H. Lundbeck A/S (Lundbeck) today announced that pipeline developments regarding amlenetug, a novel investigational molecule for the potential treatment of Multiple System Atrophy (MSA), will be ...
An orally administered drug to redistribute excess iron and lower cellular oxidative stress was found to slow disease ...
Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations – MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Alterity ...
Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...
The MS for Dwyfor Meirionnydd hosts an event at the Senedd, urging greater support for rare diseases, especially in the Welsh ...
Parkersburg WTAP-TV on MSN
West Virginia Parkinson’s and Movement Disorder Symposium
The Mid-Ohio Valley Parkinson’s Support Group’s Parkinson’s and Movement Disorder Symposium is an educational event for those ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced the completion of enrollment for REGENERATE MSA-101, its phase 1 clinical ...
Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.
Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...
Research Triangle Park, North Carolina Saturday, October 4, 2025, 13:00 Hrs [IST] ...
Could an anomaly in the developing brain explain motor difficulties occurring decades later in people with rare movement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback